| Ibrutinib resistance in chronic lymphocytic leukemia RR Furman, S Cheng, P Lu, M Setty, AR Perez, A Guo, J Racchumi, G Xu, ... New England Journal of Medicine 370 (24), 2352-2354, 2014 | 353 | 2014 |
| BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity S Cheng, J Ma, A Guo, P Lu, JP Leonard, M Coleman, M Liu, JJ Buggy, ... Leukemia 28 (3), 649-657, 2014 | 218 | 2014 |
| Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors S Cheng, A Guo, P Lu, J Ma, M Coleman, YL Wang Leukemia 29 (4), 895-900, 2015 | 177 | 2015 |
| Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals J Zhu, W Zhong, G Zhang, R Li, X Zhang, A Guo, Y Zhang, S An, TS Mok, ... Cancer letters 265 (2), 307-317, 2008 | 148 | 2008 |
| Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small … HJ Chen, TS Mok, ZH Chen, AL Guo, XC Zhang, J Su, YL Wu Pathology & Oncology Research 15, 651-658, 2009 | 139 | 2009 |
| Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL S Kadri, J Lee, C Fitzpatrick, N Galanina, M Sukhanova, G Venkataraman, ... Blood advances 1 (12), 715-727, 2017 | 125 | 2017 |
| Characterization of ibrutinib‐sensitive and‐resistant mantle lymphoma cells J Ma, P Lu, A Guo, S Cheng, H Zong, P Martin, M Coleman, YL Wang British journal of haematology 166 (6), 849-861, 2014 | 101 | 2014 |
| In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines H Cheng, SJ An, XC Zhang, S Dong, YF Zhang, ZH Chen, HJ Chen, ... Cancer chemotherapy and pharmacology 67, 637-646, 2011 | 86 | 2011 |
| Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL S Sharma, N Galanina, A Guo, J Lee, S Kadri, C Van Slambrouck, B Long, ... Oncotarget 7 (42), 68833, 2016 | 83 | 2016 |
| Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib A Guo, P Lu, N Galanina, C Nabhan, SM Smith, M Coleman, YL Wang Oncotarget 7 (4), 4598, 2016 | 72 | 2016 |
| Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays. J Bi, AL Guo, YR Lai, B Li, JM Zhong, HQ Wu, Z Xie, YL He, ZL Lv, SH Lau, ... Neoplasma 57 (3), 191-197, 2010 | 70 | 2010 |
| Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma J Ma, W Xing, G Coffey, K Dresser, K Lu, A Guo, G Raca, A Pandey, ... Oncotarget 6 (41), 43881, 2015 | 64 | 2015 |
| The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with … Q Nie, Z Wang, G Zhang, S An, J Lin, A Guo, R Li, B Gan, Y Huang, ... European Journal of Pharmacology 570 (1-3), 175-181, 2007 | 63 | 2007 |
| Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma J Lee, LL Zhang, W Wu, H Guo, Y Li, M Sukhanova, G Venkataraman, ... Blood Advances 2 (16), 2039-2051, 2018 | 59 | 2018 |
| Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients R Li, SJ An, ZH Chen, GC Zhang, JQ Zhu, Q Nie, Z Xie, AL Guo, TS Mok, ... Human pathology 39 (12), 1792-1801, 2008 | 56 | 2008 |
| Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the … A Guo, P Lu, G Coffey, P Conley, A Pandey, YL Wang Oncotarget 8 (8), 12953, 2017 | 52 | 2017 |
| RRM1 single nucleotide polymorphism-37C→ A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy S Dong, AL Guo, ZH Chen, Z Wang, XC Zhang, Y Huang, Z Xie, HH Yan, ... Journal of hematology & oncology 13 (3), 10, 2010 | 49 | 2010 |
| Surgical treatment of bone tumors in conjunction with microwave-induced hyperthermia and adjuvant immunotherapy: a preliminary report Q Fan, B Ma, A Guo, Y Li, J Ye, Y Zhou, X Qiu Chinese medical journal 109 (06), 425-431, 1996 | 42 | 1996 |
| A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro Q Zhou, AL Guo, CR Xu, SJ An, Z Wang, SQ Yang, YL Wu Clinical & Experimental Immunology 153 (3), 392-400, 2008 | 37 | 2008 |
| EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients Z Wang, YL Wu, GC Zhang, Q Zhou, CR Xu, AL Guo Oncology Research and Treatment 31 (4), 174-178, 2008 | 31 | 2008 |
